Clinical trial
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
NCT00346281 · pSiMedica Limited, Industry · Unknown status
Key facts
| NCT number | NCT00346281 |
|---|---|
| Title | 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer |
| Official title | A Phase IIa, Safety Study of the Active Implantable(Radiological) Medical Device 32P BioSilicon, Administered Intratumourally to Patients With Advanced, Unresectable Pancreatic Cancer, in Addition to Standard IV Gemcitabine Chemotherapy |
| Lead sponsor | pSiMedica Limited, Industry |
| Collaborators | pSiOncology Private Limited Singapore General Hospital Guy's and St Thomas' NHS Foundation Trust |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Device |
| Interventions | 32P BioSilicon |
| Enrollment | 15 |
| Start date | Jun 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Jun 29, 2006 |
| Last update posted | Jun 29, 2006 |
| Countries | Singapore, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: